👏 Congratulations to our PhD student Katia Montero-Diaz for her excellent presentation at the #SFMNano congress in Lyon! 👍 A great showcase of the progress taking place in our lab (Pharmacology of Inhaled Pharmaceuticals team) and within the RNAVAC consortium
At the French Symposium for Young Researchers in Cystic Fibrosis #CFJC2025, Sandra Khau, a PhD student at CEPR, received the ‘My Thesis in 3 Minutes’ award! In addition, the Michel Chignard prize, awarded prior to the conference, went to Benoit Briard, a researcher at CEPR. Congratulations to him! On 4 February, nearly 150 participants gathered at the Imagine Institute to discuss scientific advances in cystic fibrosis. Post-doctoral researchers, engineers, medical interns and master’s students presented their work through oral presentations and poster sessions, making it a particularly dynamic day. https://www.youtube.com/watch?v=cOB4XQxUVDA
CEPR was well represented at the #Biotechnocentre conference! Congratulations to our PhD students, Baptiste Rigoux and Katia Montero-Diaz, for their posters, and to our team leaders @Nathalie Heuzé-Vourc’h and @Christophe Paget for their brilliant presentations. Special mention goes to Alexis David, a third-year PhD student who won the prize for best oral presentation!
Dear Colleagues, We are pleased to announce the official opening of registration and abstract submissions (posters and oral presentations) for the joint congress of three SFBBM Thematic Groups : Enzymes, Proteolysis & Metabolism at the Crossroads of Biochemistry📅 3–5 December 2025Paris – Auditorium Buffon, Université Paris Cité (13ᵗʰ district)🌐 Conference website: https://gts-sfbbm-2025.sciencesconf.org
Congratulations to our doctoral students, Enzo Vidy, Katia Montero-Diaz, and postdoctoral researcher Bhupinder Kaur, for their excellent presentations at the PEPR Biotherapies and Bioproduction of Innovative Therapies conference in Montpellier! A wonderful showcase of the advances being made at CEPR. #France2030 #PEPR #Biotherapies #Bioproduction
Brilliant presentation of Margaux’s PhD work at the 20th edition of the Microbes Congress, organized by the Société Française de Microbiologie! She had the opportunity to present part of my PhD work on post-influenza aspergillosis superinfections, and to exchange with an outstanding community of researchers, clinicians, and fellow students. 🦠🍄
👏 Very proud of the CEPR INSERM Lab PhD students!! Oral presentation and posters for the Centre-Val de Loire Region PhD Day. 😀 Congratulations, you are flying the flag for your laboratory! University of Tours – Inserm
The Team 3 (Virginie Hervé, Sandrine Le Guellec & Mike Pasteur) was recently on air during La Méridienne, the daily radio show on Radio Campus Tours 99.5 FM! We had a very enjoyable time sharing our work with Melissa Wyckhuyse, as we discussed the different in vitro models developed in our lab for the advancement of new inhaled therapies. 👏 Many thanks to Melissa Wyckhuyse, Pierre DaSilva (Ph.D.), and Jean-Michel Escoffre, Ph.D., for organizing this inspiring edition of Les Méridiennes! 🎧 You can listen to the full episode of the show via the podcast by clicking >Here<
The EU-funded FAIR project has reached a major milestone with the start of a Phase I clinical trial for FLAMOD, an innovative therapy targeting respiratory infections. The trial is being conducted at the Clinical Investigation Centre of the Academic Hospital of Tours, France, led by Prof. Antoine Guillon. Unlike traditional antibiotics, FLAMOD boosts the body’s own immune response and is designed to work alongside antibiotics to improve their effectiveness. Derived from flagellin—a natural bacterial component—FLAMOD is delivered via aerosol using an Aerogen mesh nebulizer to directly stimulate lung immunity without triggering widespread inflammation. “This is a novel approach that directly addresses the challenge of antibiotic resistance,” said Prof. Guillon, highlighting the burden of respiratory infections, which cause around 3 million deaths globally each year. Dr. Valérie Gissot, Head of the Investigation Centre, emphasized the unique academic origins of the project: “Unlike most drug developments, FLAMOD was conceived and advanced by researchers and clinicians within academia, made possible by EU funding.” The NEBUFLAG trial crowns five years of collaborative work under the FAIR project. Coordinator Dr. Jean-Claude Sirard praised the team’s efforts: “This marks the first human trial with nebulized flagellin. Our progress in preclinical studies, dose modeling, and trial design has been exceptional.” The trial is expected to conclude by the end of 2026, with early results already showing promise.
